Association of Weight Change, Inflammation Markers and Disease Staging with Survival of Patients Undergoing Chemotherapy for Pancreatic Adenocarcinoma

References

• Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019;10(1):10–27. doi:https://doi.org/10.14740/wjon1166
   PubMedGoogle Scholar
• International Agency for Research on Cancer - World Health Organization. Globocan 2018. Population Fact Sheets: Portugal. 2018;270:2018–9. http://gco.iarc.fr/today/fact-sheets-populations%0A http://gco.iarc.fr/today/data/factsheets/populations/620-portugal-fact-sheets.pdf.
   Google Scholar
• Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, et al.; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10. doi:https://doi.org/10.1056/NEJMoa032295
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. Cancer J Clin. 2018;68(1):7–30. doi:https://doi.org/10.3322/caac.21442
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul J-L, Gourgou-Bourgade S, de la Fouchardière C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. doi:https://doi.org/10.1056/NEJMoa1011923
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhang B, Han Y, Jiang Y, Zhuang Q, Gong Y, Wu G. Survey of cachexia in digestive system cancer patients and its impact on clinical outcomes. Zhonghua Wei Chang Wai Ke Za Zhi 2014;(17):968–71.
   PubMedGoogle Scholar
• Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol [Internet]. 2011;12(5):489–95. doi:https://doi.org/10.1016/S1470-2045(10)70218-7
   PubMed Web of Science ®Google Scholar
• Tripp MK. Pancreatic cancer-induced cachexia and relevant mouse models. Physiol Behav. 2017;176(1):139–48.
   PubMedGoogle Scholar
• Ozola Zalite I, Zykus R, Francisco Gonzalez M, Saygili F, Pukitis A, Gaujoux S, Charnley RM, Lyadov V. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: A systematic review. Pancreatology 2015;15(1):19–24. doi:https://doi.org/10.1016/j.pan.2014.11.006
   PubMed Web of Science ®Google Scholar
• Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(11):1039–49. doi:https://doi.org/10.1056/NEJMra1404198
   PubMed Web of Science ®Google Scholar
• Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Prim [Internet]. 2018;4:1–18. doi:https://doi.org/10.1038/nrdp.2017.105
   PubMedGoogle Scholar
• Laird BJ, Kaasa S, McMillan DC, Fallon MT, Hjermstad MJ, Fayers P, Klepstad P. Prognostic factors in patients with advanced cancer: A comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res. 2013;19(19):5456–64. doi:https://doi.org/10.1158/1078-0432.CCR-13-1066
   PubMed Web of Science ®Google Scholar
• Loumaye A, Thissen JP. Biomarkers of cancer cachexia. Clin Biochem. 2017;50(18):1281–8. doi:https://doi.org/10.1016/j.clinbiochem.2017.07.011
   PubMed Web of Science ®Google Scholar
• Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DSJ, Foulis AK, Horgan PG, McMillan DC. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: A Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104(4):726–34. doi:https://doi.org/10.1038/sj.bjc.6606087
   PubMed Web of Science ®Google Scholar
• Imaoka H, Mizuno N, Hara K, Hijioka S, Tajika M, Tanaka T, Ishihara M, Yogi T, Tsutsumi H, Fujiyoshi T, et al. Evaluation of modified Glasgow prognostic score for pancreatic cancer: A retrospective cohort study. Pancreas 2016;45(2):211–7. doi:https://doi.org/10.1097/MPA.0000000000000446
   PubMed Web of Science ®Google Scholar
• Howard R, Kanetsky PA, Egan KM. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Sci Rep. 2019;9(1):1–10. ]. doi:https://doi.org/10.1038/s41598-019-56218-z
   PubMedGoogle Scholar
• Mowbray NG, Griffith D, Hammoda M, Shingler G, Kambal A, Al-Sarireh B. A meta-analysis of the utility of the neutrophil-to-lymphocyte ratio in predicting survival after pancreatic cancer resection. HPB. 2018;20(5):379–84. doi:https://doi.org/10.1016/j.hpb.2017.12.009
   PubMedGoogle Scholar
• Ventriglia J, Petrillo A, Huerta Alváro M, Laterza MM, Savastano B, Gambardella V, Tirino G, Pompella L, Diana A, Iovino F, et al. Neutrophil to lymphocyte ratio as a predictor of poor prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine: A propensity score analysis. Gastroenterol Res Pract. 2018;2018:1–7. doi:https://doi.org/10.1155/2018/2373868
   Google Scholar
• Zhou Y, Wei Q, Fan J, Cheng S, Ding W, Hua Z. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A meta-analysis containing 8252 patients. Clin Chim Acta 2018;479(January):181–9. [Internet]. Available from: doi:https://doi.org/10.1016/j.cca.2018.01.024
   PubMedGoogle Scholar
• Kays JK, Shahda S, Stanley M, Bell TM, O'Neill BH, Kohli MD, Couch ME, Koniaris LG, Zimmers TA. Three cachexia phenotypes and the impact of fat-only loss on survival in folfirinox therapy for pancreatic cancer. J Cachexia Sarcopenia Muscle 2018;9(4):673–84. doi:https://doi.org/10.1002/jcsm.12307
   PubMed Web of Science ®Google Scholar
• Vega MD, Laviano A, Pimentel GD. Sarcopenia and chemotherapy-mediated toxicity. Einstein (Sao Paulo) 2016;14(4):580–4. doi:https://doi.org/10.1590/S1679-45082016MD3740
   PubMedGoogle Scholar
• Barreto SG. Pancreatic cancer: Let us focus on cachexia, not just sarcopenia!. Future Oncol. 2018;14(27):2791–4. doi:https://doi.org/10.2217/fon-2018-0369
   PubMedGoogle Scholar
• Piciucchi M, Stigliano S, Archibugi L, Zerboni G, Signoretti M, Barucca V, Valente R, Fave FF, Capurso G. The neutrophil/lymphocyte ratio at diagnosis is significantly associated with survival in metastatic pancreatic cancer patients. Int J Mol Sci. 2017;18(4):3–11.
   Google Scholar
• Giakoustidis A, Neofytou K, Costa Neves M, Giakoustidis D, Louri E, Cunningham D, Mudan S. Identifying the role of neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio as prognostic markers in patients undergoing resection of pancreatic ductal adenocarcinoma. Ann Hepatobiliary Pancreat Surg. 2018;22(3):197–207. doi:https://doi.org/10.14701/ahbps.2018.22.3.197
   PubMedGoogle Scholar
• Gao Y, Wang W-J, Zhi Q, Shen M, Jiang M, Bian X, Gong F-R, Zhou C, Lian L, Wu M-Y, et al. Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresectable pancreatic cancer. Oncotarget 2017;8(51):88835–44. doi:https://doi.org/10.18632/oncotarget.21340
   PubMedGoogle Scholar
• Derman BA, Macklis JN, Azeem MS, Sayidine S, Basu S, Batus M, Esmail F, Borgia JA, Bonomi P, Fidler MJ, et al. Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer. BMC Cancer 2017;17(1):1–6. doi:https://doi.org/10.1186/s12885-017-3122-y
   PubMedGoogle Scholar
• Coffelt S, Wellenstein M, de Visser K. Neutrophils in cancer: Neutral no more. Nat Rev Cancer 2016;16(7):431–46. doi:https://doi.org/10.1038/nrc.2016.52
   PubMed Web of Science ®Google Scholar
• Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Büchler MW, Friess H, Martignoni ME. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg. 2008; 12(7):1193–201. doi:https://doi.org/10.1007/s11605-008-0505-z
   PubMed Web of Science ®Google Scholar
• Fearon KC, Voss AC, Hustead DS. Definition of cancer cachexia: Effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr. 2006;83(6):1345–50. doi:https://doi.org/10.1093/ajcn/83.6.1345
   PubMed Web of Science ®Google Scholar
• Sullivan ES, Daly LE, Bhuachalla ÉBN, Cushen SJ, Power DG, Ryan AM. Loss of adipose tissue mass during chemotherapy predicts reduced survival in patients with colorectal cancer treated with palliative intent. Proc Nutr Soc. 2020;79(OCE2):2020.
   Google Scholar
• Gannavarapu BS, Lau SKM, Carter K, Cannon NA, Gao A, Ahn C, Meyer JJ, Sher DJ, Jatoi A, Infante R, et al. Prevalence and survival impact of pretreatment cancer-associated weight loss: A tool for guiding early palliative care. J Oncol Pract. 2018;14(4):e238–e250. doi:https://doi.org/10.1200/JOP.2017.025221
   PubMedGoogle Scholar
• Argilés JM, Betancourt A, Guàrdia-Olmos J, Peró-Cebollero M, López-Soriano FJ, Madeddu C, Serpe R, Busquets S. Validation of the CAchexia SCOre (CASCO). Staging cancer patients: The use of mini CASCO as a simplified tool. Front Physiol. 2017;8(FEB):1–9.
   PubMedGoogle Scholar
• Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, Baptista G, Barazzoni R, Blaauw R, Coats AJS, et al.; GLIM Core Leadership Committee, GLIM Working Group. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. J Cachexia Sarcopenia Muscle 2019;10(1):207–17. doi:https://doi.org/10.1002/jcsm.12383
   PubMed Web of Science ®Google Scholar
• Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, Deans C, Strasser F, Thoresen L, Jagoe RT, Chasen M, et al. Diagnostic criteria for the classification of cancer-associated weight loss. JCO. 2015;33(1):90–9. doi:https://doi.org/10.1200/JCO.2014.56.1894
   PubMed Web of Science ®Google Scholar
• Solheim TS, Laird BJA, Balstad TR, Bye A, Stene G, Baracos V, Strasser F, Griffiths G, Maddocks M, Fallon M, et al. Cancer cachexia: Rationale for the MENAC (Multimodal - Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial. BMJ Support Palliat Care 2018;1;8(3):258–65. doi:https://doi.org/10.1136/bmjspcare-2017-001440
   PubMed Web of Science ®Google Scholar